Beyond the horizon: Neutrophils leading the way in the evolution of immunotherapy

Cancer Med. 2023 Dec;12(24):21885-21904. doi: 10.1002/cam4.6761. Epub 2023 Dec 7.

Abstract

Cancer is a complex and dynamic disease, initiated by a multitude of intrinsic mutations and progressed with the assistance of the tissue microenvironment, encompassed by stromal cells including immune cell infiltration. The novel finding that tumors can evade anti-cancer immune functions shaped the field of immunotherapy, which has been a revolutionary approach for the treatment of cancers. However, the development of predominantly T cell-targeted immunotherapy approaches, such as immune checkpoint inhibition, also brought about an accumulation of evidence demonstrating other immune cell drivers of tumor progression, such as innate immune cells and notably, neutrophils. In the past decade, neutrophils have emerged to be primary mediators of multiple cancer types and even in recent years, are gaining attention for their potential use in the next generation of immunotherapies. Here, we review current immunotherapy strategies and thoroughly discuss the roles of neutrophils in cancer and novel neutrophil-targeted methods for treating cancer.

Keywords: cancer; immunotherapy; neutrophils; tumor microenvironment.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy / methods
  • Neoplasms* / pathology
  • Neutrophils*
  • T-Lymphocytes
  • Tumor Microenvironment